Live cell molecular analysis of primary prostate cancer organoids identifies persistent androgen receptor signaling

Erika Héninger(University of Wisconsin Carbone Cancer Center), Joshua M. Lang(University of Wisconsin–Madison)
Medical Oncology
September 28, 2021
10.1007/s12032-021-01582-y
Cited by 20

Related Papers

Sacituzumab govitecan, a Trop-2-directed antibody-drug conjugate, for patients with epithelial cancer: final safety and efficacy results from the phase I/II IMMU-132-01 basket trial
|Annals of Oncology|2021|371
NCCN Guidelines® Insights: Prostate Cancer, Version 1.2023.
|PubMed|2022|172
Reversible epigenetic alterations regulate class I HLA loss in prostate cancer
|Communications Biology|2022|52
Expression and Therapeutic Targeting of TROP-2 in Treatment-Resistant Prostate Cancer
|Clinical Cancer Research|2023|52
Live Cell Sorting of Differentiated Primary Human Osteoclasts Allows Generation of Transcriptomic Signature Matrix
|Research Square|2025|0